Marker Therapeutics, Inc. has announced a collaboration with Cellipont Bioservices to support the cGMP manufacturing of MT-601, its lead Multi-Antigen Recognizing (MAR)-T cell therapy, currently in ...
Marker was awarded 2023 FreeMind Elite honoree, a group of FreeMind Group clients that are selected annually and honored for their achievements in pursuing non-dilutive funding. To date, Marker has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results